Evenity Injection contains the active ingredient Romosozumab, a humanized monoclonal antibody that promotes bone formation while simultaneously inhibiting bone resorption. It belongs to the anti-osteoporotic agent’s class and is primarily indicated for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. By increasing bone mineral density and strength, injection of Evenity reduces the risk of both vertebral and non-vertebral fractures in patients with severe osteoporosis. This treatment is particularly recommended for individuals who have not responded well to other osteoporosis therapies.

Evenity Injection uses include reducing the likelihood of fractures in postmenopausal women who have experienced multiple fractures or are at risk due to significantly low bone mass. It is administered as a subcutaneous injection once a month for 12 months. Evenity injection dose is typically 210 mg per month, provided as two consecutive injections. Patients are usually transitioned to anti-restorative therapy following the completion of the 12-month course to maintain the benefits gained.

Although effective, it is essential to be aware of Evenity injection side effects, which may include joint pain, headache, injection site reactions, and, in rare cases, an increased risk of cardiovascular events. Patients with a history of heart attack or stroke should avoid this medication. Evenity injection instructions must be followed carefully to minimize potential adverse effects. It is advised to monitor calcium and vitamin D levels during treatment to prevent hypocalcemia. For those considering this treatment, Evenity injection reviews highlight its effectiveness in improving bone density and reducing fractures. However, it is essential to consult a healthcare provider to assess individual risks and benefits, as the cost of Evenity injection can be high.

Treatment of osteoporosis in postmenopausal women at high risk of fracture.

Reducing the incidence of vertebral and non-vertebral fractures.

Romosozumab, the active ingredient in Evenity Injection, works by inhibiting sclerostin, a regulatory protein involved in bone metabolism. By blocking sclerostin, Romosozumab leads to increased bone formation and decreased bone resorption, resulting in improved bone mineral density (BMD) and reduced risk of fractures.

Evenity Injection should be administered once a month as a subcutaneous injection, usually in the upper arm, abdomen, or thigh. Each dose of Romosozumab should be administered by a healthcare professional as per your doctor’s instructions. It is vital to maintain adequate levels of calcium and vitamin D during treatment to minimize the risk of hypocalcemia.

Joint pain

Headache

Injection site reactions

Muscle pain

Fatigue

Cardiovascular events such as heart attack or stroke

Hypocalcaemia (low calcium levels)

Evenity Injection may interact with other medications. Inform your doctor of all medications you are taking, especially calcium supplements, vitamin D supplements, or other osteoporosis medications.

Store the injection in the refrigerator between 2°C to 8°C.

Do not freeze.

Keep it out of reach of children.

This medication should be administered as prescribed by your healthcare provider. Evenity Injection is typically given as a subcutaneous injection by a healthcare professional once a month. It is important to follow your doctor's instructions regarding the timing and dosage. Inform your doctor about any history of allergies, heart conditions, kidney or liver problems, and other medications you are taking, especially for calcium, vitamin D, or other bone-related treatments, before starting this medication.

Avoid driving or operating heavy machinery if you experience side effects of Evenity injections, such as dizziness or fatigue, after receiving this injection. Ensure that your calcium and vitamin D levels are monitored and maintained during treatment. Regular monitoring of your heart health, liver function, and calcium levels is advised while using this medication.